A Double Blind, Randomized Trial of Alirocumab and Plaque Regression in Peripheral Arterial Disease

Trial Profile

A Double Blind, Randomized Trial of Alirocumab and Plaque Regression in Peripheral Arterial Disease

Recruiting
Phase of Trial: Phase IV

Latest Information Update: 26 Jul 2017

At a glance

  • Drugs Alirocumab (Primary)
  • Indications Peripheral arterial disorders
  • Focus Therapeutic Use
  • Most Recent Events

    • 20 Jul 2017 Planned End Date changed from 1 Jun 2020 to 17 Jul 2020.
    • 20 Jul 2017 Planned primary completion date changed from 1 Jun 2019 to 17 Jul 2019.
    • 20 Jul 2017 Status changed from not yet recruiting to recruiting.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top